Nghĩa của từ allogene bằng Tiếng Việt
alen lặn, gen đẳng vị lặ
Đặt câu có từ "allogene"
1. 8 Allogene Therapeutics reviews
2. Cancer startup Allogene Therapeutics Inc
3. View the latest Allogene Therapeutics Inc
4. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering …
5. Allogene Therapeutics 25,382 followers on LinkedIn
6. Allogene Therapeutics is funded by 14 investors.
7. Allogene Therapeutics is registered under the ticker NASDAQ:ALLO
8. Allogene Therapeutics is now valued at $5 billion
9. Allogene will provide funding, developmental candidates and other support
10. Allogene Therapeutics is a clinical stage immuno-oncology company
11. Up to 10% cash back · Allothigenic SpringerLink allogene.
12. Allogene Therapeutics shares have increased 14% since the beginning of the year
13. MD Anderson already is collaborating with Allogene on two phase 1/phase 2 …
14. Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company
15. Allogene Therapeutics has raised a total of $531.8M in funding over 2 rounds
16. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
17. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
18. Allogene Therapeutics Inc (NASDAQ:ALLO) Q1 2020 Earnings Call May 06, 2020, 8:30 a.m
19. Led by a management team with significant experience in cell therapy, Allogene is developing a
20. Allogene Therapeutics's (NASDAQ:ALLO) stock has been rising Wednesday, up 4.29% to a price of $34.17
21. Allogene has raised $300 in Series A fundraising, and $120 million in a private financing round
22. 1 day ago · Allogene Therapeutics shares have increased 14% since the beginning of the year
23. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf
24. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell
25. Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies
26. Allogene Therapeutics has raised close to US$800M in funds since April 2018 and assembled a superstar leadership team
27. Allogene Therapeutics, Inc. Common Stock (ALLO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
28. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf
29. Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of Allogeneic CAR T (AlloCAR T™) therapies for cancer
30. Allogene finished Q3 with a net loss of $50.7 million, up from a $43.5 million net loss in the year-ago quarter
31. Allogene will present more detailed results, including data from five additional patients, at the American Society of Hematology's virtual meeting next month.
32. On October 11, 2018, Allogene Therapeutics raised $324 million in an initial public offering on the NASDAQ, listing under the ticker "ALLO".
33. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy
34. Allogene is backed by a $300-million investment from a consortium of venture-capital and investment firms; Pfizer will retain a 25% ownership
35. Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for …
36. Allogene is among them, having been formed in 2018 with $300 million and a portfolio of treatments that originated within French firms Cellectis and Servier
37. Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial
38. Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of Allogeneic CAR T cell therapy Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that …
39. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T-cell (CAR T
40. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T
41. South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma
42. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of …
43. 1 day ago · Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric …
44. Allogene Therapeutics, Inc.’s ALLO CAR T cell product candidate — ALLO-715 — has been given Regenerative Medicine Advanced Therapy (“RMAT”) designation by the FDA for treating relapsed
45. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
46. Allogene used the enthusiasm generated by the positive ALLO-501 data in late May to conduct an equity capital raise, procuring net proceeds of $595.7 million at $47 a share.
47. Allogene reported an overall response rate of 78% in a phase 1 trial of its off-the-shelf CAR-T ALLO-501 combined with the antibody ALLO-647
48. Through a variety of cross-licensing and shared-commercialization rights, two other companies, Servier and Cellectis, are involved in the deal as well, and Allogene is taking over commercialization of a
49. The French biotech Servier has an agreement with Allogene Therapeutics, through Pfizer, to market its Allogenic chimeric antigen receptor (CAR) T-cell product in the United States if it receives
50. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer